Navigation Links
Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
Date:2/22/2010

s an enormous unmet need to help reduce the individual and economic burden of obesity," said Christian Weyer, M.D., vice president, medical development at Amylin Pharmaceuticals. "Through our global co-development and commercialization agreement with Takeda, we are committed to developing innovative therapies to help the millions of people who need better solutions to manage obesity. Today's announcement is an important step forward in helping us make good on that commitment."

"We are pleased with the results of the Phase 2 extension study for the pramlintide/metreleptin combination therapy," said Nancy Joseph-Ridge, M.D., general manager of Takeda's Pharmaceutical Development Division. "This potential new therapy continues to build on our commitment to the management of obesity."

In this extension of a 28-week Phase 2 dose-ranging study, patients who continued treatment with pramlintide/metreleptin for a total of 52 weeks demonstrated sustained weight loss, whereas those continuing on placebo regained almost all of their weight. Consistent with results at 28 weeks, the most robust efficacy was seen in patients with a body mass index (BMI) less than 35 kg/m2.

The combination therapy appeared to be generally well tolerated through 52 weeks, with nausea and injection site adve
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amylin Pharmaceuticals to Webcast Year-End Financial Results
2. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
3. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
4. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
7. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
8. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
9. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
10. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
11. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  AliveCor, Inc. announced today ... (FDA) has granted the company clearance for ... the most common form of cardiac arrhythmia. ... if patients are experiencing AFib through real-time ... phone based AliveCor® Heart Monitor, so physicians ...
(Date:8/21/2014)... , Aug. 21, 2014 Professional Compounding ... paediatric medicine by awarding the three best scientific ... initiative (EuPFI) conference . The Formulating Better ... 18 in Athens, Greece , ... students and professionals, from which three winners will ...
(Date:8/21/2014)... CYBX ) today announced results for the quarter ...   Operating results for the first quarter of ... and other achievements, include: , Worldwide net product sales ... international net sales of $13.2 million, an increase of 14.5% ... sales reached a new high of $58.8 million, an increase ...
Breaking Medicine Technology:AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16
... Sigma-Aldrich® (Nasdaq: SIAL ) today announced ... Inc., a Berks County, PA. -based provider of ... Animals ( www.aceanimals.com ), a commercial rodent breeder established ... services, and will operate as part of Sigma Advanced ...
... NATICK, Mass. and ATLANTA , ... BSX ) today announced results from an analysis ... assessing the impact of diabetes on clinical and angiographic ... Express2™ Paclitaxel-Eluting Stent System or the Express® ...
Cached Medicine Technology:Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 2Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 3Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 4Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 5Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 6Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 7Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 2Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 3Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 4Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 5Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 6
(Date:8/21/2014)... San Diego, CA (PRWEB) August 21, 2014 ... this year, is a short but powerful collection of ... meant to uplift and inspire other budding entrepreneurs on ... honored and proud to announce the inclusion of President ... and insight from highly successful and self-made celebrities such ...
(Date:8/21/2014)... ERT, a leading global solution ... endpoint data collection, today opened registration for ... Product Value with Optimized Endpoints. The ... developers to network with leading researchers as ... implementing, and justifying effective strategies for collecting ...
(Date:8/21/2014)... Early diagnosis of diabetic peripheral neuropathy is important ... group at the Fourth Affiliated Hospital of Kunming ... sought to establish a sensitive index for nerve ... neuropathy in 500 patients with diabetes mellitus. Nerve ... longer, sensory nerve conduction velocity was slower, and ...
(Date:8/21/2014)... 21, 2014 The ... Vascular Devices Market by Angioplasty Balloon ... (IVUS, OCT), IVC Filter (Retrievable), Endovascular ... analyzes and studies the major market ... U.S. and Canada. , Browse 108 ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Artisan Business ... & Investment Exploratory Delegation to southern China October 12-19, ... to explore the rapid growing cities of Shenzhen and ... will have the rare opportunity to meet with major ... during a short weeklong time frame. , The ...
Breaking Medicine News(10 mins):Health News:Earth Source Organics President Audrey Darrow Featured in New David Mullings Book 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Artisan Business Group announces 2014 EB-5 Investment Trade Mission to China 2
... June 5 (HealthDay News) -- The human body has two ... and the "good" brown kind that burns them. Now, researchers ... fat to help people lose weight. "We are now ... treating obesity and diabetes," study lead author Dr. Aaron Cypess, ...
... -- ASCO Abstract #CRA9015. Flaxseed provides no benefit in ... and postmenopausal women, according to a Mayo Clinic ... (NCCTG) study. The randomized, placebo-controlled study was conducted on ... no statistically significant difference in mean hot flash scores ...
... a study that included nearly 18,000 children who had cancer, ... associated with a subsequent primary neoplasm (a new tumor) at ... neoplasms (related to the genital or urinary tract organs), according ... JAMA , a theme issue on cancer. The study is ...
... a woman,s skin wrinkles are during the first few years ... will be presented Monday at The Endocrine Society,s 93rd Annual ... the skin may offer a glimpse of the skeletal well-being, ... reproductive endocrinologist and associate professor at Yale School of Medicine, ...
... HealthDay Reporter , FRIDAY, June 3 (HealthDay News) -- U.S. ... little chance the deadly new strain of E. coli bacteria ... impact here. "This outbreak has not affected the ... Administration,s Regional Operations, said during a Friday afternoon news conference. ...
... -- A mutant gene long thought to accelerate tumor ... of malignant cells, showing promise for novel cancer therapies, ... will be presented by Mayo Clinic researcher Honey Reddi, ... Dr. Reddi,s discovery could have widespread implications in cancer ...
Cached Medicine News:Health News:Brown Fat Cells May One Day Help Combat Obesity 2Health News:Mayo Clinic: Flaxseed no cure for hot flashes during breast cancer or menopause 2Health News:Childhood cancer survivors at increased risk of certain tumors in middle-age 2Health News:Childhood cancer survivors at increased risk of certain tumors in middle-age 3Health News:Severity of facial wrinkles may predict bone density in early menopause 2Health News:Officials: U.S. Not Affected by European E. Coli Outbreak 2Health News:Officials: U.S. Not Affected by European E. Coli Outbreak 3Health News:Fighting cancer with cancer: Mayo Clinic finds promising use for thyroid cancer gene 2
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
circuitGuard™ Products are available in filter or filter/HME styles., ,High quality air cushion anesthesia masks may be packaged with any circuitGuard™ product....
... Since 1991 Intersurgical Incorporated ... filters, heat and moisture ... therapy products, hand-held nebulizers ... of accessories and connectors ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: